Clinical trials: Demyelinating Disorder
Multiple Sclerosis, Chronic Pain
Virtual Reality (VR) to Improve Quality of Life in Patients Diagnosed With Neurological Disorders
Participants with neurological disorders will be recruited to complete sessions of virtual reality (VR) immersion. VR has been shown to have therapeutic benefit in certain patient populations and requires further clinical study…
- Conditions
- Multiple Sclerosis, Chronic Pain, Neurological Disorder
- Trial name
- NCT03606668
- Testing
- HTC Vive Virtual Reality (VR) system
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Relapsing-remitting Multiple Sclerosis, RRMS
POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler
A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by MRI scans over a 24 week period in patients with…
- Trial name
- NCT01051817
- Testing
- AIN457
- Where
- 16 sites in Czechia, Russia and 1 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing, Remitting
Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients
This study is planned to evaluate emotional disorders during treatment by interferon (IFN) beta in relapsing remitting multiple sclerosis (RRMS) subjects.
- Trial name
- SEPTIME (NCT01201343)
- Testing
- Interferon beta-1a
- Volunteers
- 79 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)
The purpose of this study is to determine changes on overall gait as well as in multiple gait and balance parameters after withdrawal of dalfampridine-ER 10mg in MS subjects who are receiving the medication consistently for at…
- Trial name
- NCT01535664
- Testing
- Withdrawal of dalfampridine-ER 10mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Acorda Therapeutics
Multiple Sclerosis, Cognitive Impairment
Non-invasive Transcranial Electrical Stimulation in MS
The goal is to investigate the effects of non-invasive transcranial electrical stimulation on cognition in MS.
- Trial name
- NCT04466228
- Testing
- non-invasive transcranial electrical stimulation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, San Francisco
Multiple Sclerosis
Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis
Study design is double-blind, randomized, placebo-controlled study in 3 parallel groups with the use of active comparator and placebo. Total duration of therapy of about 2 years.
- Trial name
- NCT02727907
- Testing
- BCD-033 (interferon beta 1a), Rebif (interferon beta 1a)
- Where
- Russia
- Volunteers
- 163 people
- Sponsor
- Biocad
Multiple Sclerosis
Evaluation of a Spasticity Management Program for People With Multiple Sclerosis
This study will examine the impacts of two different methods of managing MS-related spasticity of the lower limbs. Both interventions will be presented via video teleconference in group classes consisting of exercises to reduce…
- Trial name
- STC (NCT03166930)
- Testing
- Spasticity Take Control, Stretching for People with MS: An Illustrated Manual
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- VA Office of Research and Development
Fibromyalgia, Multiple Sclerosis
e-Mobile Tablet for People With Chronic Conditions
Maintaining a healthy diet and engaging in routine physical activity may help decrease severity of symptoms, prevent secondary conditions, and slow functional decline in people with disabling neuromusculoskeletal conditions.
- Conditions
- Fibromyalgia, Multiple Sclerosis, Osteoarthritis, Sjögren's Syndrome
- Trial name
- NCT02833311
- Testing
- Computer Tablet Group, Paper and Pencil Group, Contact Control Group
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Case Western Reserve University
Multiple Sclerosis
Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
The primary objective of the study was to evaluate the immunogenicity of Avonex® (interferon beta-1a) 30 mcg when administered subcutaneously (SC) to interferon-naïve participants with relapsing multiple sclerosis.
- Trial name
- NCT00784836
- Testing
- BG9418 (interferon beta 1-a)
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Biogen
Multiple Sclerosis, Back Pain
A Pilot Project for Multifidus Muscle Evaluation in Patients With Multiple Sclerosis
This research study plans to evaluate if multifidus muscle dysfunction is associated with back pain in patients with Multiple Sclerosis (MS).
- Trial name
- NCT05427045
- Testing
- home - exercise program
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Arkansas
Relapsing-remitting Multiple Sclerosis
Natalizumab De-escalation With Interferon Beta-1b
Multiple Sclerosis (MS) is the most common neurological disorder causing disability in young adults. The management of MS-patients requires treatment with disease-modifying agents, monoclonal antibodies such as natalizumab or…
- Trial name
- NCT01144052
- Testing
- interferon beta-1b, Natalizumab
- Where
- Switzerland
- Volunteers
- 19 people
- Sponsor
- Claudio Gobbi
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS)
- Trial name
- NCT05000216
- Testing
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S
- Where
- 29 sites in United States
- Volunteers
- 258 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Relapsing-remitting Multiple Sclerosis
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
The study was to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a (Avonex®), once a week intramuscularly in participants with RMS.
- Trial name
- NCT04032158
- Testing
- Evobrutinib, Avonex®
- Where
- 2 sites in United States, Germany
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Multiple Sclerosis
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
Primary Objective: To assess the effect of teriflunomide in comparison to placebo on disease activity measured by time to first clinical relapse after randomization in children and adolescents 10 to 17 years of age with relapsing…
- Trial name
- TERIKIDS (NCT02201108)
- Testing
- Teriflunomide
- Where
- 57 sites in United States, Belgium and 20 more
- Volunteers
- 166 people
- Sponsor
- Genzyme, a Sanofi Company
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
The primary objective of the study is to evaluate the safety and tolerability of BG00012 (dimethyl fumarate) administered in combination with interferon b (IFNß) or glatiramer acetate (GA) in participants with relapsing-remitting…
- Trial name
- EXPLORE (NCT01156311)
- Testing
- dimethyl fumarate
- Where
- 16 sites in United States
- Volunteers
- 108 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
Safety of New Formulation of Glatiramer Acetate
The purpose of this study is to compare pain associated with injections and injection-site reactions of the approved formulation of Glatiramer Acetate (GA) versus investigational formulation of GA.
- Trial name
- Song (NCT00947752)
- Testing
- Glatiramer Acetate, Experimental Glatiramer Acetate
- Volunteers
- 147 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis, Relapsing-Remitting
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
The purpose of this study was to establish the efficacy and safety of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous (SC) interferon beta-1a (Rebif®).
- Trial name
- CARE-MS I (NCT00530348)
- Testing
- Alemtuzumab, Interferon beta-1a
- Where
- 101 sites in United States, Argentina and 14 more
- Volunteers
- 581 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
The main objective of the study is to evaluate the efficacy of dimethyl fumarate (Tecfidera) and peginterferon beta-1a (Plegridy), both compared with placebo, in pediatric participants with RRMS.
- Trial name
- NCT03870763
- Testing
- Dimethyl Fumarate, Peginterferon Beta-1a
- Where
- 23 sites in United States, Colombia and 11 more
- Volunteers
- 11 people
- Sponsor
- Biogen
Multiple Sclerosis
Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)
The primary purpose of this study was to evaluate the long-term effectiveness of Mavenclad® tablets, in terms of disease activity and safety, in participants with highly-active relapsing multiple sclerosis (RMS) previously…
- Trial name
- NCT04783935
- Testing
- Mavenclad®
- Where
- 46 sites in Australia, Austria and 12 more
- Volunteers
- 219 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Relapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Patient Research Cohort: Rapidly Evolving Multiple Sclerosis
The primary goal of the research cohort is to facilitate patient access to clinical trials testing new therapeutic interventions, or access to second- line treatments.
- Trial name
- PRC-REMS (NCT01044576)
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Imperial College London